Low Molecular Weight Chondroitin Sulfate Sodium (LMWCS, CAS 9082-07-9) is chondroitin sulfate depolymerized to 5-15 kDa versus standard CS at 20-50 kDa. Standard CS oral absorption is only ~10-13% because the intestinal epithelial tight junction pore size limits passive paracellular transport to molecules <~500 Da; standard CS (20-50 kDa) is far too large and must first be partially degraded by colonic microbiota into smaller fragments before absorption can occur. LMWCS at 5-15 kDa achieves 30-40% oral bioavailability — approximately 3× higher than standard CS — through two synergistic mechanisms: (1) significantly reduced hydrodynamic radius enables enhanced paracellular transport through intestinal tight junctions, and (2) polyanionic oligosaccharides (5-15 kDa) additionally exploit transcellular caveolae-mediated endocytosis, an active transport pathway inaccessible to the larger standard CS polymer. At equivalent oral doses (1,200 mg/day), LMWCS delivers ~3× more biologically active chondroitin to synovial fluid and systemic circulation. This bioavailability advantage is clinically significant and directly driven by molecular weight reduction.

LMWCS (5-15 kDa) delivers three clinically significant benefit categories. Joint Health: 3× higher oral bioavailability means more chondroitin reaches synovial fluid; smaller CS fragments more effectively block TLR4/MD-2 and inhibit NF-κB signaling (enhanced cell membrane permeability and receptor accessibility) for superior anti-inflammatory activity at equivalent doses; supports cartilage matrix integrity through chondroitin sulfate proteoglycan synthesis. Skin Anti-Aging: 5-15 kDa CS penetrates the stratum corneum via transfollicular and intercellular aqueous pathways — while the stratum corneum typically limits molecules >500 Da, CS is polyanionic and exploits these alternative routes, enabling topical delivery of biologically active chondroitin to the dermis where it supports GAG synthesis, inhibits MMPs, and provides deep hydration. Wound Healing: LMWCS promotes fibroblast proliferation, angiogenesis, and organized collagen deposition in wound beds; the smaller MW enables incorporation into advanced hydrogel and nanofiber wound dressing scaffolds with superior release kinetics compared to standard CS. LMWCS is the only single bioactive ingredient that addresses joint health (oral), skin anti-aging (topical), and wound healing (topical) across three distinct therapeutic areas.

UPOR Biotech produces LMWCS via controlled hydrogen peroxide (H₂O₂) oxidation depolymerization at 37°C, pH 7.4. The mechanism: H₂O₂ generates hydroxyl radicals (•OH) via a Fenton-like reaction with trace transition metals; these •OH radicals selectively cleave glycosidic bonds in the chondroitin sulfate backbone through hydrogen abstraction at glycosidic positions, progressively reducing molecular weight from the starting 20-50 kDa to the target 5-15 kDa range. Critically, H₂O₂ oxidation preserves the intact 4S sulfation pattern (ΔDi-4S ≥65% maintained post-depolymerization) because •OH radical attack targets the polysaccharide backbone rather than sulfate ester groups — sulfate hydrolysis requires acidic conditions or dedicated sulfatase enzymes, neither of which is present in the controlled H₂O₂ process. In contrast, enzymatic depolymerization using chondroitinase ABC introduces a Δ4,5-unsaturated uronic acid residue at the non-reducing end of each fragment, fundamentally altering the disaccharide structure and potentially affecting receptor recognition (TLR4, CD44) and biological activity. UPOR’s H₂O₂ process produces LMWCS with native-like chemical structure and preserved bioactivity, confirmed by GPC-MALLS (Mw 5-15 kDa, polydispersity Mw/Mn ≤2.0) and SAX-HPLC disaccharide analysis on every batch.

Low MW chondroitin sulfate (5-15 kDa) occupies a unique position among joint health and skincare ingredients. Versus Standard Chondroitin (20-50 kDa): LMWCS provides 3× higher oral bioavailability, enhanced anti-inflammatory activity via superior TLR4/MD-2 inhibition, better skin penetration for topical applications, and higher solubility/lower viscosity for formulation versatility — while delivering the same core chondroitin sulfate bioactivity (sulfated GAG structure, cartilage matrix support). Versus Glucosamine: Glucosamine is a monosaccharide precursor (MW 179 Da) that provides raw material for GAG synthesis but lacks the direct anti-inflammatory, TLR4-blocking, and MMP-inhibiting bioactivity of intact chondroitin sulfate oligosaccharides; LMWCS and glucosamine are complementary — LMWCS provides the bioactive effector while glucosamine supplies biosynthetic substrate. Versus Hyaluronic Acid: HA is a non-sulfated GAG specialized for water retention and viscoelasticity (MW 10⁹-10⁷ Da); LMWCS is a sulfated GAG with receptor-mediated bioactivity (TLR4, CD44, chemokine interactions); they serve complementary roles — HA for hydration and rheology, LMWCS for anti-inflammatory signaling and tissue repair. LMWCS offers unique dual joint + skin benefits from a single bioavailable ingredient that neither glucosamine nor HA can replicate.

Every shipment includes: COA (HPLC purity ≥90%/≥95%/≥98% per grade, GPC-MALLS molecular weight report with Mw, Mn, Mw/Mn polydispersity index, SAX-HPLC disaccharide composition with ΔDi-4S%/ΔDi-6S%/ΔDi-0S%/ΔDi-diS%, heavy metals ≤10 ppm with Pb ≤2 ppm/As ≤1 ppm/Hg ≤1 ppm/Cd ≤1 ppm, microbial panel per USP <61>/<62>), MSDS, GPC-MALLS Chromatogram (signed and dated), SAX-HPLC Disaccharide Analysis Report, Depolymerization Process Certificate (H₂O₂ oxidation method, batch conditions documented), Sulfation Pattern Preservation Certificate (ΔDi-4S ≥65% confirmation), BSE/TSE-Free Statement, Non-GMO Statement, Allergen Statement, HALAL Certificate, KOSHER Certificate, ISO 22000 + HACCP, ISO 9001:2015, FDA Facility Registration, Stability Data (25°C/60%RH real-time 36-month and 40°C/75%RH accelerated 6-month), and Complete Lot Traceability from source material through depolymerization to finished LMWCS powder. Free sample available for qualified B2B buyers. MOQ: 1 kg. All documents provided in English.